Last reviewed · How we verify

Choroidal retinal neovascularization — Treatment Landscape & Competitive Intelligence

Choroidal retinal neovascularization (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Choroidal retinal neovascularization, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Visudyne VERTEPORFIN Bausch Lomb Ireland Photoenhancer [EPC] 2000-01-01
Lucentis Lucentis Santen Inc. Vascular endothelial growth factor A
BYOOVIZ RANIBIZUMAB-NUNA SAMSUNG BIOEPIS CO LTD Vascular endothelial growth factor A
Visudyne Visudyne Bayer

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Bausch Lomb Ireland · 1 drug in Choroidal retinal neovascularization
  2. Bayer · 1 drug in Choroidal retinal neovascularization
  3. SAMSUNG BIOEPIS CO LTD · 1 drug in Choroidal retinal neovascularization
  4. Santen Inc. · 1 drug in Choroidal retinal neovascularization

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Choroidal retinal neovascularization:

Cite this brief

Drug Landscape (2026). Choroidal retinal neovascularization — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/choroidal-retinal-neovascularization. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing